Effect of Immunochemotherapy Sequence and Time-of-day Infusion on Efficacy and Prognosis of Patients With Advanced Esophageal Squamous Cell Carcinoma
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 350
- 试验地点
- 1
- 主要终点
- Overall survival
研究概览
简要总结
It is reported that compared to chemotherapy alone, immunochemotherapy has significantly improved the overall survival of patients with advanced metastatic ESCC. However, there are still more than 30% of patients who cannot benefit from this treatment modality. In addition to these factors, the time-of-day infusion and administration sequence of immunochemotherapy have been reported to be associated with tumor responses and overall survival. In this study, The investigators aimed to explore the roles of infusion time and administration sequence of immunochemotherapy in predicting tumor responses and overall survival in patients with advanced ESCC.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 78 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Pathologically diagnosed as esophageal squamous cell carcinoma
- •Adequate organ function
- •No distant metastasis
- •The diseases could be resected or potentially resectable after immunochemotherapy assessed by a thoracic oncologist
排除标准
- •incomplete medical record which affects statistical analysis
- •have participated in previous interventional clinical trials
- •other situations evaluated by investigators not meet the enrollment
结局指标
主要结局
Overall survival
时间窗: from the date of diagnosis to the date of death, assessed up to 100 months
Overall survival rate
次要结局
- Pathologic complete response rate (pCR)(Three to five working days after surgery)